Making Sense of the Current SPAC Market: Are SPACs still a viable pathway to going public?
Within the past year the role in biotech of special purpose acquisition companies (SPAC) has moved from a rarefied interest to a core option for reaching public markets, now attracting high levels of investor and regulator attention. Learn through live Q&A with a panel of SPAC deal experts how this popular, volatile tool for raising capital works in
practice and will evolve next.
Find out more and register.
Barbara Ryan, Founder, Barbara Ryan Advisors; Editorial Advisory Board, Pharmaceutical Executive; Senior Advisor, EY
Jonas Grossman, President and Managing Partner, Chardan
Rakhi Kumar, Chief Accounting Officer, Roivant Sciences
Ryan Maierson, Partner, Latham & Watkins LLP
Carlo Passeri, Director, Biotechnology Capital Markets, Biotechnology Innovation Organization (BIO)